Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
Items 301–400 of 899
Control of nucleolar stress and translational reprogramming by lncRNAs
Verheyden, Y., Goedert, L., & Leucci, E. (2019) · Cell Stress · doi:10.15698/cst2019.01.172 · Cited by 30
“pathological context, is corroborated by the number of compounds targeting these processes currently in the clinic [49].”
BackgroundHuman WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation
Cai, W. L., Chen, J. F.-Y., Chen, H., Wingrove, E., Kurley, S. J., Chan, L.-H., Zhang, M., Estape, A. A., Zhao, M., Balabaki, A., et al. (2022) · eLife · doi:10.7554/elife.78163 · Cited by 30
Roy, A., & Kumar, A. (2022) · Nature Communications · doi:10.1038/s41467-022-29752-0 · Cited by 29
Villalobos-Manzo, R., Ríos‐Castro, E., Hernández-Hernández, J. M., Oza, G., Salcedo, J. M. M., & Tapia-Ramírez, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081715 · Cited by 29
“This dysregulation is often associated with aberrant function and perturbations in the expression of components of the translation machinery in cancer [32,33].”
BackgroundLi, F., Sun, H., Yu, Y., Che, N., Han, J., Cheng, R.-F., Zhao, N., Guo, Y., Huang, C., & Zhang, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05841-w · Cited by 29
“It has been shown that in TNBC, patients with high eIF4E expression are more likely to relapse and have a higher mortality rate than those with low eIF4E expression [19].”
Lineham, E., Tizzard, G. J., Coles, S. J., Spencer, J., & Morley, S. (2018) · Oncotarget · doi:10.18632/oncotarget.24354 · Cited by 29
“This addiction to increased protein synthesis provides a therapeutic window to selectively target the translational machinery of cancer cells [13, 14].”
BackgroundGoing (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
Bourhill, T., Mori, Y., Rancourt, D. E., Shmulevitz, M., & Johnston, R. N. (2018) · Viruses · doi:10.3390/v10080421 · Cited by 29
Zakaria, C., Sean, P., Hoang, H., Leroux, L., Watson, M., Workenhe, S. T., Hearnden, J., Pearl, D., Truong, V. T., Robichaud, N., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007264 · Cited by 29
“In addition, the mTORC1 signaling pathway is often hyperactivated in cancer resulting in elevated phosphorylation of 4E-BPs [21].”
BackgroundSelf-citationRamalingam, S., Ramamurthy, V. P., Gediya, L. K., Murigi, F. N., Purushottamachar, P., Huang, W., Choi, E. Y., Zhang, Y., Vasaitis, T. S., Kane, M. A., et al. (2019) · Cancers · doi:10.3390/cancers11030299 · Cited by 29
Miao, B., Wei, C., Qiao, Z., Han, W., Chai, X., Lu, J., Gao, C., Dong, R., Gao, D., Huang, C., et al. (2019) · PubMed · Cited by 29
cat-ELCCA: catalyzing drug discovery through click chemistry
Garner, A. L. (2018) · Chemical Communications · doi:10.1039/c8cc02332h · Cited by 28
MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma
Ke, X., Chen, Y., Tham, V. Y.-Y., Lin, R. Y., Dakle, P., Nacro, K., Puhaindran, M. E., Houghton, P. J., Pang, A. S. L., Lee, V. K. M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01661-4 · Cited by 28
Bayoumi, A., Elsayed, A., Han, S., Petta, S., Adams, L. A., Aller, R., Khan, A., García‐Monzón, C., Arias, M., Miele, L., et al. (2021) · Advanced Science · doi:10.1002/advs.202004168 · Cited by 28
Proteome diversification by mRNA translation in cancer
Kochavi, A., Lovecchio, D., Faller, W. J., & Agami, R. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.11.014 · Cited by 28
Wang, S., Darini, C., Désaubry, L., & Koromilas, A. E. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0416 · Cited by 28
“In addition to FL3, potent inhibitors of eIF4A activity, such as silvestrol or hippuristanol, have been considered for the treatment of various forms of cancer (36).”
BackgroundWilliam, M., Leroux, L., Chaparro, V., Graber, T. E., Alain, T., & Jaramillo, M. (2019) · European Journal of Immunology · doi:10.1002/eji.201847857 · Cited by 28
Bentayeb, H., Aitamer, M., Petit, B., Dubanet, L., Elderwish, S., Désaubry, L., Gramont, A. D. E., Raymond, É., Olivrie, A., Abraham, J., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1440-4 · Cited by 28
Walker, M. J. P., Shortridge, M. D., Albin, D., Cominsky, L. Y., & Varani, G. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.001 · Cited by 28
Selective Translation of Cell Fate Regulators Mediates Tolerance to Broad Oncogenic Stress
Cai, E. Y., Kufeld, M., Schuster, S. L., Arora, S., Larkin, M., Germanos, A. A., Hsieh, A. C., & Beronja, S. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.05.007 · Cited by 28
“5 HrasG12V epidermis at clonal density (MOI<1) with a lentivirus pool of 1228 shRNAs targeting 195 translation initiation factors, elongation factors, ribosomal proteins, tRNA synthetases, and poly(A) binding proteins (Bhat et al., 2015; Moffat et al., 2006) (Figure 1F).”
BackgroundDehua, D., Chen, H., Tang, J. P., & Tang, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.025 · Cited by 28
NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., et al. (2021) · Cancers · doi:10.3390/cancers13040639 · Cited by 27
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
BackgroundLi, F., Sun, H., Li, Y., Bai, X., Dong, X., Zhao, N., Meng, J., Sun, B., & Zhang, D. (2021) · BMC Cancer · doi:10.1186/s12885-021-09010-0 · Cited by 27
“Previous studies have shown that patients with high expression of eIF4E are more likely to relapse and have higher mortality than those with minimal expression of eIF4E in triple-negative BRCA (TNBC) [8].”
BackgroundInfluentialAlanazi, A. S., Mirgany, T. O., Alsfouk, A. A., Alsaif, N. A., & Alanazi, M. M. (2023) · Medicina · doi:10.3390/medicina59030610 · Cited by 27
“A single drug may successfully destroy cells holding a specific alteration while cells driven by other stimulants persist [28].”
BackgroundKwegyir‐Afful, A. K., Murigi, F. N., Purushottamachar, P., Ramamurthy, V. P., Martin, M. S., & Njar, V. C. O. (2016) · Oncotarget · doi:10.18632/oncotarget.14154 · Cited by 27
“Inhibitors targeting the Mnk1/2-eIF4E axis are actively under investigation for the treatment of several cancers [13].”
BackgroundA Large-Scale RNAi Screen Identifies SGK1 as a Key Survival Kinase for GBM Stem Cells
Kulkarni, S., Goel-Bhattacharya, S., Sengupta, S., & Cochran, B. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0146 · Cited by 27
“The targeting of these pathways is not ideal due to their critical functions in many normal cells, but may be effective due to the dysregulation and hyperactivation of these pathways in cancer tissues (32, 33).”
BackgroundMarcon, B. H., Holetz, F., Eastman, G., Origa-Alves, A. C., Amorós, M., de Aguiar, A. M., Rebelatto, C. L. K., Brofman, P. R. S., Sotelo-Silveira, J. R., & Dallagiovanna, B. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.10.027 · Cited by 27
Regulation of cellular gene expression by nanomaterials
Chun, S. H., Yuk, J. S., & Um, S. H. (2018) · Nano Convergence · doi:10.1186/s40580-018-0166-x · Cited by 27
Howard, C. M., Bearss, N. R., Subramaniyan, B., Tilley, A. M. C., Sridharan, S., Villa, N., Fraser, C. S., & Raman, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00284 · Cited by 27
“therapy against TNBC breast cancer progression and metastasis (23, 59, 83).”
BackgroundYin, J., Chen, J., Hong, J. H., Huang, Y., Xiao, R., Liu, S., Deng, P., Sun, Y.-C., Chai, K. X. Y., Zeng, X., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.177857 · Cited by 26
“These findings suggested that SLC7A11 dictates the sensitivity of OV cells to ferroptosis induced by MEK inhibitors. mTOR/4EBP1 pathway modulates SLC7A11 protein synthesis to promote ferroptosis escape upon trametinib treatment . mTOR signaling pathway is associated with protein translation (21–23).”
BackgroundBetts, H., Sephton, S. M., Tong, C., Awais, R. O., Hill, P. J., Perkins, A. C., & Aigbirhio, F. I. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00968 · Cited by 26
Huang, Y.-Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79227 · Cited by 26
“Most importantly, increased cellular protein synthesis is often characterized in malignant growth [19].”
Wang, D., Jia, Y., Zheng, W., Li, C., & Cui, W. (2019) · Disease Markers · doi:10.1155/2019/6019637 · Cited by 26
“Second, the overexpression of single eIF3 subunit and/or the resulting upregulation of the entire eIF3 complex would induce a more efficient translation initiation rate of specific mRNAs, which is known as a common feature in cancer [27].”
BackgroundLIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy
Missios, P., da Rocha, E. L., Pearson, D. S., Philipp, J., Aleman, M. M., Pirouz, M., Farache, D., Franses, J. W., Kubaczka, C., Tsanov, K. M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145142 · Cited by 26
“Lentiviral production To produce lentiviral particles, HEK293T cells were transfected with Therapeutic targeting of the translational machinery in highly aggressive cancers has been previously suggested (49, 54, 55), and various compounds that inhibit ribosomal biogenesis have shown therapeutic potential (4).”
BackgroundNeural stemness unifies cell tumorigenicity and pluripotent differentiation potential
Zhang, M., Liu, Y., Shi, L., Fang, L., Xu, L., & Cao, Y. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102106 · Cited by 26
“Inhibition of the activity of these machineries has been either applied to cancer therapy or under clinical trials (Bennett and Licht, 2018; Bhat et al., 2015; Bustelo and Dosil, 2018; Chen et al., 2017; Dvinge et al., 2016; Mohammad et al., 2019; Pelletier et al., 2018; Soave et al., 2017; Thibaudeau and Smith, 2019;…”
MethodCárdenas, E. L., O’Rourke, R. L., Menon, A., Meagher, J. L., Stuckey, J. A., & Garner, A. L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00917 · Cited by 26
“eIF4E is an RNA-binding protein that plays two important roles in the initiation of cap-dependent translation: (1) eIF4E binds to the m7GpppX-cap at the 5¢ terminus of coding mRNAs to promote the assembly of the eIF4F translation initiation complex, and (2) it promotes the nuclear export of select cap-dependent transc…”
RNA binding protein: coordinated expression between the nuclear and mitochondrial genomes in tumors
Ma, J., Sun, L., Gao, W., Yang, L., & Dong, D. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04373-3 · Cited by 26
A tRF ‐5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1
Huang, T., Chen, C., Du, J., Zheng, Z., Ye, S., Fang, S., & Liu, K. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17982 · Cited by 26
“54 Recently it has been suggested that the MKNK-eIF4E axis is critically involved in various cancers.”
BackgroundRibavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors
Casaos, J., Huq, S., Lott, T., Felder, R., Choi, J. H., Gorelick, N. L., Peters, M., Xia, Y., Maxwell, R., Zhao, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23883 · Cited by 26
“In addition, we analyzed levels of eIF4E and phospho-eIF4E, which are known to play a pivotal role in protein synthesis and are upregulated in many malignancies [25].”
MethodPham, T. D., Kumar, K., DeCant, B. T., Shang, M., Munshi, S. Z., Matsangou, M., Ebine, K., & Munshi, H. G. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0768 · Cited by 26
“Cancer cells can also develop resistance by activating the translational machinery (12).”
BackgroundHanna, K., Asiedu, A.-L., Theurer, T., Muirhead, D. K., Speirs, V., Oweis, Y. G., & Eid, R. A. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.26 · Cited by 25
“21).”
Humphries, M. P., Rajan, S. S., Droop, A., Suleman, C. A. B., Carbone, C., Nilsson, C., Honarpisheh, H., Cserni, G., Dent, J., Fulford, L. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1952 · Cited by 25
“Indeed, most of the direct inhibitors of the eIF machinery are targeted toward eIF4E [28].”
BackgroundCap-dependent translation initiation monitored in living cells
Gandin, V., English, B. P., Freeman, M., Leroux, L., Preibisch, S., Walpita, D., Jaramillo, M., & Singer, R. H. (2022) · Nature Communications · doi:10.1038/s41467-022-34052-8 · Cited by 25
Alanazi, M. M., & Alanazi, A. S. (2023) · Molecules · doi:10.3390/molecules28155869 · Cited by 25
“Following this strategy (mutikinase inhibition) in cancer treatment will avoid treating cancer with either single drug treatment, which is unable to destroy all cells holding multiple stimuli, or using multiple anticancer agents that will increase toxicity and drug–drug interaction [18].”
BackgroundInfluentialProbing the Anticancer Action of Novel Ferrocene Analogues of MNK Inhibitors
Sansook, S., Lineham, E., Hassell‐Hart, S., Tizzard, G. J., Coles, S. J., Spencer, J., & Morley, S. (2018) · Molecules · doi:10.3390/molecules23092126 · Cited by 25
Kisly, I., Rèmme, J., & Tamm, T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1083 · Cited by 25
Gallagher, E. E., Song, J. M., Menon, A., Mishra, L. D., Chmiel, A. F., & Garner, A. L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00068 · Cited by 25
Kim, H. (2019) · Biomolecules · doi:10.3390/biom9110665 · Cited by 25
Manfrini, N., Ricciardi, S., Miluzio, A., Fedeli, M., Scagliola, A., Gallo, S., Brina, D., Adler, T., Busch, D. H., Gailus‐Durner, V., et al. (2017) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2017.07.022 · Cited by 25
“Initiation is the rate limiting step of 355 translation (Loreni et al., 2014; Sonenberg and Hinnebusch, 2009) and mounting evidence indicates 356 that targeting the translational machinery is feasible and leads to specific effects (Bhat et al., 2015).”
BackgroundJin, P., Wang, X., Jin, Q., Zhang, Y., Shen, J., Jiang, G., Zhu, H., Zhao, M., Wang, D., Li, Z., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2543 · Cited by 24
RNPS1 stabilizes NAT10 protein to facilitate translation in cancer via tRNA ac4C modification
Wang, X., Ling, R., Cheng, M., Xu, H., Chen, D., Peng, X., Ling, R., Chen, J., Wan, Y., Ke, L., et al. (2024) · International Journal of Oral Science · doi:10.1038/s41368-023-00276-7 · Cited by 24
Waye, S. E., Naeem, A., Choudhry, M. U., Parasido, E., Tricoli, L., Sivakumar, A., Mikhaiel, J. P., Yenugonda, V. M., Rodriguez, O. C., Karam, S. D., et al. (2015) · Aging · doi:10.18632/aging.100831 · Cited by 24
“MNK1 is a target of p38 and MAPK and acts to increase CAPdependent translation through the phosphorylation of the elongation factor eIF4E [28].”
Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies
Villanueva, E., Navarro, P., Rovira-Rigau, M., Sibilio, A., Méndez, R., & Fillat, C. (2017) · Nature Communications · doi:10.1038/ncomms14833 · Cited by 24
Li, X., Li, B., Ni, Z., Zhou, P., Wang, B., He, J., Xiong, H., Yang, F., Wu, Y., Lyu, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0763 · Cited by 24
“Recently, targeting protein translation has emerged as a novel therapeutic strategy to fight against cancers and overcome intratumor heterogeneity (37).”
BackgroundA side-effect free method for identifying cancer drug targets
Ashraf, M. I., Ong, S., Mujawar, S., Pawar, S., More, P., Paul, S., & Lahiri, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-25042-2 · Cited by 24
Cuesta, R., Berman, A. Y., Alayev, A., & Holz, M. K. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004383 · Cited by 25
PABPC1 Relevant Bioinformatic Profiling and Prognostic Value in Gliomas
Wang, Q., Wang, Z., Bao, Z., Zhang, C., Wang, Z., & Jiang, T. (2019) · Future Oncology · doi:10.2217/fon-2019-0268 · Cited by 24
Critical Roles of METTL3 in Translation Regulation of Cancer
Meng, W., Han, X., Mei, P., Chen, J., Wang, Y., Zhao, R., & Liao, Y. (2023) · Biomolecules · doi:10.3390/biom13020243 · Cited by 23
“Components of the translational machinery integrate almost all oncogenic signals [22], and dysregulation of the translational process is considered one of the hallmarks of tumors and is associated with abnormal proliferation, angiogenesis, differentiation, and immune response [23,24].”
BackgroundHigh-Throughput Chemical Probing of Full-Length Protein–Protein Interactions
Song, J. M., Menon, A., Mitchell, D. C., Johnson, O. T., & Garner, A. L. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.7b00128 · Cited by 23
Dolgikh, N., Hugle, M., Vogler, M., & Fulda, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1737 · Cited by 23
Role of Notch Signaling in Colorectal Cancer
Rajendran, D. T., Subramaniyan, B., & Ganeshan, M. (2017) · Springer eBooks · doi:10.1007/978-981-10-6728-0_21 · Cited by 23
Hwang, H. S., Lee, M. H., & Kim, H. (2020) · The FASEB Journal · doi:10.1096/fj.201903003r · Cited by 23
Zeng, L., Tang, M., Pi, C., Zheng, J., Gao, S., Chabanne, T., Chauvin, R., Cheng, W., Lin, H., Xu, R., et al. (2021) · Cancers · doi:10.3390/cancers13184677 · Cited by 23
“In addition, mTOR is viewed as another PI3K/Akt/mTOR signaling pathway downstream component which could also be phosphorylated by Akt [48].”
BackgroundCao, Y. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10275-y · Cited by 23
“Translation initiation factors are also usually upregulated in cancers and correlate with disease progression and poor prognosis [165].”
BackgroundFernando, R. C., de Carvalho, F., Mazzotti, D. R., Evangelista, A. F., Braga, W. M. T., Chauffaille, M. D. L., Leme, A. F. P., & Colleoni, G. W. B. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.88 · Cited by 23
“Protein biosynthesis is an extremely important process for normal function of our cells and organisms as a whole and, therefore, is strictly regulated in order to ensure that it occurs properly [19].”
Backgroundc-Myc deregulation induces mRNA capping enzyme dependency
Lombardi, O., Varshney, D., Phillips, N. M., & Cowling, V. H. (2016) · Oncotarget · doi:10.18632/oncotarget.12701 · Cited by 23
“Inhibiting the function and interactions of the translation initiation complex, eIF4F, interferes with cap-dependent translation and is also being investigated as a therapeutic strategy [68].”
BackgroundAlshamsan, A., Khan, S., Imran, A., Aljuffali, I. A., & AlSaleh, K. A. (2017) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.05.007 · Cited by 23
“Control of translation is a critical component for the progress and advancement of cancer (Bhat et al., 2015; Silvera et al., 2010).”
BackgroundInhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma
Cao, J., Sun, X., Zhang, X., & Chen, D. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1786-z · Cited by 23
Garrido, M. F., Martin, N. J.-P., Bertrand, M., Gaudin, C., Commo, F., Kalaany, N. E., Nakouzi, N. A., Fazli, L., Nery, E. D., Camonis, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0704 · Cited by 23
“We believe that targeting translation machinery is a promising strategy for minimizing acquired resistance (45).”
BackgroundRNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications
Huang, S., Li, Z., Lin, W., Xie, R., & Huang, H. (2025) · MedComm · doi:10.1002/mco2.70322 · Cited by 22
Thus, Y. J., de Rooij, M. F. M., Swier, N., Beijersbergen, R. L., Guikema, J. E. J., Kersten, M. J., Eldering, E., Pals, S. T., Kater, A. P., & Spaargaren, M. (2022) · Haematologica · doi:10.3324/haematol.2022.281668 · Cited by 22
“39 Furthermore, the phosphorylation of ribosomal protein S6 has been implicated in translation initiation.”
EIF4G1 Is a Potential Prognostic Biomarker of Breast Cancer
Li, K., Tan, G., Zhang, X., Lu, W., Ren, J., Si, Y., Adu‐Gyamfi, E. A., Li, F., Wang, Y., Xie, B., et al. (2022) · Biomolecules · doi:10.3390/biom12121756 · Cited by 22
Alanazi, A. S., Mirgany, T. O., Alsaif, N. A., Alsfouk, A. A., & Alanazi, M. M. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.05.003 · Cited by 22
“A single anticancer drug may effectively kill cancer cells holding a single alteration, nevertheless, other cells motivated by additional signaling will persist (Bhat et al., 2015).”
Herrmannová, A., Jelínek, J., Pospíšilová, K., Kerényi, F., Vomastek, T., Watt, K., Brábek, J., Mohammad, M. P., Wagner, S., Topisirović, I., et al. (2024) · eLife · doi:10.7554/elife.95846.3 · Cited by 22
Han, W., Ding, Y., Xu, Y., Pfister, K. B., Zhu, S., Warne, B., Doyle, M., Aikawa, M., Amiri, P., Appleton, B. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01657 · Cited by 22
Targeting of protein translation as a new treatment paradigm for prostate cancer
Ramamurthy, V. P., Ramalingam, S., Kwegyir‐Afful, A. K., Hussain, A., & Njar, V. C. O. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000367 · Cited by 22
Antiviral Drug Ribavirin Targets Thyroid Cancer Cells by Inhibiting the eIF4E-β-Catenin Axis
Shen, X., Zhu, Y., Xiao, Z., Dai, X., Liu, D., Li, L., & Xiao, B. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.03.025 · Cited by 22
“eIF4E overexpression and activation correlates with poor clinical outcomes in various human cancers.(6,9) The correlation of eIF4E overexpression with the progression of thyroid carcinoma, in particular, has also been demonstrated.”
BackgroundFiocchetti, M., Cipolletti, M., Ascenzi, P., & Marino, M. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26378 · Cited by 22
“…positive SK-BR-3 cells strongly sustain the role of AKT in preventing NGB degradation as reported in other cell lines and for other proteins (Bhat et al., 2015; Gwak, Kim, An, Dhanasekaran, & Song, 2017; Lum et al., 2005; Noguchi, Hirata, & Suizu, 2014; Yamaguchi, Hsu, & Hung, 2012) and to…”
BackgroundFatehi, D., Soltani, A., & Ghatrehsamani, M. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.04.001 · Cited by 22
The Secret Life of Translation Initiation in Prostate Cancer
Hernández, G., Ramírez, J. L., Pedroza‐Torres, A., Herrera, L. A., & Jiménez-Ríos, M. Á. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00014 · Cited by 22
Overcoming Paradoxical Kinase Priming by a Novel MNK1 Inhibitor
Bou‐Petit, E., Hümmer, S., Alarcon, H., Slobodnyuk, K., Cano-Galietero, M., Fuentes, P. J. B., Guijarro, P. J., Muñoz, M. J., Suárez‐Cabrera, L., Santamaría, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01941 · Cited by 22
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167651 · Cited by 21
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
Champagne, J., Nielsen, M. M., Feng, X., Navarro, J. M., Pataskar, A., Voogd, R., Giebel, L., Nagel, R., Berenst, N., Fumagalli, A., et al. (2025) · Immunity · doi:10.1016/j.immuni.2024.12.004 · Cited by 21
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy
Gitareja, K., Chelliah, S. S., Sanij, E., Sandhu, S. K., Kang, J., & Khot, A. S. (2025) · Cancers · doi:10.3390/cancers17152534 · Cited by 21
“In addition to impairing ribosome biogenesis, several strategies have been explored to directly interfere with the translation machinery, particularly through targeting components of the eIF4F complex, such as eIF4E, eIF4G, and eIF4A [199] (Figure 5).”
Termathe, M., & Leidel, S. A. (2021) · Biomolecules · doi:10.3390/biom11020139 · Cited by 21
Ju, Y., Ben‐David, Y., Rotin, D., & Zacksenhaus, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-88816-1 · Cited by 21
Zafirov, D., Giovinazzo, N., Lecampion, C., Field, B., Ducassou, J. N., Couté, Y., Browning, K. S., Robaglia, C., & Gallois, J. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011417 · Cited by 21
Uddin, M. B., Wang, Z., & Yang, C. (2024) · Advanced Science · doi:10.1002/advs.202403936 · Cited by 21
The translation factors of Drosophila melanogaster
Marygold, S. J., Attrill, H. L., & Lasko, P. F. (2016) · Fly · doi:10.1080/19336934.2016.1220464 · Cited by 21
Cancer as an ecomolecular disease and a neoplastic consortium
y Cajal, S. R., Capdevila, C., Hernández‐Losa, J., Mattos‐Arruda, L. D., Ghosh, A., Lorent, J., Larsson, O. S., Aasen, T., Postovit, L.-M. M., & Topisirović, I. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.09.004 · Cited by 21
“Differences in translational programs between normal and cancer cells are thought to provide a sufficient therapeutic window to selectively target cancer cells while causing minimal toxicity in normal tissues (127,128).”
BackgroundMegat, S., & Price, T. J. (2018) · Neurobiology of Pain · doi:10.1016/j.ynpai.2018.02.001 · Cited by 21
“From the perspective of developing therapeutics, these intricate signaling pathways that regulate translation provide many opportunities for intervention (for a recent comprehensive review on the topic see: (Bhat et al., 2015)).”
Serine-threonine protein phosphatases: Lost in translation
KOLUPAEVA, V. G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.006 · Cited by 21
“As one of the most energetically expensive cellular processes, it is tightly regulated, predominantly at the initiation step by phosphorylation/ dephosphorylation of the eukaryotic initiation factors (eIFs) [1].”
BackgroundRodriguez, K. X., Howe, E. N., Bacher, E. P., Burnette, M. D., Meloche, J. L., Meisel, J. E., Schnepp, P. M., Tan, X., Chang, M., Zartman, J. J., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900266 · Cited by 21
Herzog, L.-O., Walters, B., Buono, R., Lee, J. S., Mallya, S., Fung, A., Chiu, H., Nguyen, N., Li, B., Pinkerton, A. B., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01205-9 · Cited by 21
Translation initiation and its relevance in colorectal cancer
Minnee, E., & Faller, W. J. (2020) · FEBS Journal · doi:10.1111/febs.15690 · Cited by 21
Methyltransferase like 13 mediates the translation of Snail in head and neck squamous cell carcinoma
Wang, X., Li, K., Wan, Y., Chen, F., Cheng, M., Xiong, G., Wang, G., Chen, S., Chen, Z., Chen, J., et al. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00130-8 · Cited by 21
Vahidfar, N., Farzanefar, S., Ahmadzadehfar, H., Molloy, E. N., & Eppard, E. (2022) · Cancers · doi:10.3390/cancers14071779 · Cited by 21
Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma
Scagliola, A., Miluzio, A., & Biffo, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054885 · Cited by 21
“The general involvement of eIF4F in the progression of cancer is well established and is part of a complex research area that aims at its pharmacological targeting [20,49,85].”
BackgroundJastrzebski, K., Thijssen, B., Kluin, R. J. C., de Lint, K., Majewski, I. J., Beijersbergen, R. L., & Wessels, L. F. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2698 · Cited by 21
“Although everolimus is an allosteric inhibitor of predominantly mTOR complex 1 (mTORC1), active-site inhibitors are able to target both mTORC1 and mTORC2 (30).”
BackgroundProtein phase separation: A novel therapy for cancer?
Wang, W., Chen, Y., Xu, A., Cai, M., Cao, J., Zhu, H., Yang, B., Shao, X., Ying, M., & He, Q. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15242 · Cited by 21
“Many oncogenes (MYC, RAS and PIK3CA) and tumour suppressors (PTEN and TP53) can affect the translation machinery, making aberrant translation a common characteristic of tumour cells (Bhat et al., 2015; Chalhoub & Baker, 2009; Prior, Lewis, & Mattos, 2012).”
BackgroundWu, S., & Wagner, G. (2021) · Cell Systems · doi:10.1016/j.cels.2021.07.002 · Cited by 20
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.